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ABSTRACT
Patients suffering from systemic autoimmune diseases are at
significant risk of cardiovascular complications. This can be due to
systemically increased levels of inflammation leading to accelerated
atherosclerosis, or due to direct damage to the tissues and cells of the
heart. Cardiac complications include an increased risk of myocardial
infarction, myocarditis and dilated cardiomyopathy, valve disease,
endothelial dysfunction, excessive fibrosis, and bona fide
autoimmune-mediated tissue damage by autoantibodies or auto-
reactive cells. There is, however, still a considerable need to better
understand how to diagnose and treat cardiac complications in
autoimmune patients. A range of inducible and spontaneous mouse
models of systemic autoimmune diseases is available for mechanistic
and therapeutic studies. For this Review, we systematically collated
information on the cardiac phenotype in the most common inducible,
spontaneous and engineered mouse models of systemic lupus
erythematosus, rheumatoid arthritis and systemic sclerosis. We also
highlight selected lesser-known models of interest to provide
researchers with a decision framework to choose the most suitable
model for their study of heart involvement in systemic autoimmunity.
KEY WORDS: Heart disease, Heart failure, Mouse model,
Myocarditis, SLE, Systemic autoimmunity
Introduction
Aberrant activation of the immune system by self-antigens can lead to
systemic autoimmune diseases such as systemic lupus erythematosus
(SLE), rheumatoid arthritis (RA) and systemic sclerosis (SSc), and
results in autoimmune-mediated tissue destruction. Autoimmune and
cardiovascular diseases generally affect distinct demographic groups,
yet patients suffering from systemic autoimmunity are at increased
risk of developing cardiac complications (Jastrzeb̨ska et al., 2013).
While increased cardiovascular morbidity and mortality in
autoimmune patients have previously been attributed to accelerated
atherosclerosis (Abou-Raya and Abou-Raya, 2006), we now
appreciate that increased systemic inflammation and anti-heart auto-
reactivity also directly affect cardiac cells and tissues (Knockaert,
2007). Fig. 1 shows the heart structures affected by SLE, RA and SSc,
and the frequency of complications involving these structures.
Our understanding of the interplay between the cardiovascular and
the immune system has seen a dramatic increase in recent years. This
is largely due to the use of rodent models, which allow true
mechanistic and cause-and-effect studies. Notably, however, animal
models of autoimmune disease are rarely fully homologous to the
human condition and generally only exhibit select features of the
disease. It is further necessary to appreciate the cause of cardiac
effects, which may include accelerated atherosclerosis, endothelial
dysfunction, fibroblast activation, and autoantibody and cell-
mediated autoimmune damage (see Box 1 for a glossary of terms).
It is therefore crucial to choose the right model or combination of
models for a selected phenotype or mechanism (Fig. 2).
A range of well-established mouse models of SLE, RA and SSc
are available and commonly used in the immunological community.
Yet, while the need to better understand, diagnose and treat cardiac
involvement in systemic autoimmunity has become apparent,
cardiac effects were rarely the focus of studies using these models
and data on cardiac involvement is surprisingly scarce.
Systemic lupus erythematous
SLE is a multisystem autoimmune disorder with diverse clinical
features, including arthritis and haematological, cutaneous, renal and
neurological manifestations (Kaul et al., 2016). It most commonly
affects women and its development is influenced by a combination of
genetic, environmental and hormonal factors (Lisnevskaia et al.,
2014). SLE is characterised by the presence of anti-nuclear antibodies
(ANAs), including anti-Smith (anti-Sm), anti-double-stranded-DNA
(anti-dsDNA), anti-Ro and anti-La (Box 1) autoantibodies (Han
et al., 2015). Triggers, including apoptotic cell debris, activate Toll-
like receptors (TLRs) on plasmacytoid dendritic cells (pDCs) and
induce excessive type I interferon (IFN) production. This causes
immune system dysregulation and promotes antigen presentation to T
cells (Crow et al., 2015; Kaul et al., 2016). T cells derived from SLE
patients show persistent upregulation of co-stimulatory molecules,
leading to increased activation and differentiation of autoantibody-
producing B cells (Koshy et al., 1996). Likewise, B cell regulation is
impaired, augmenting the production of autoantibodies and cytokines
and promoting complement activation, ultimately resulting in tissue
damage via immune-complex deposition (Kaul et al., 2016).
Cardiac involvement in patients with SLE can affect all components
of the cardiovascular system (Fig. 1). A systematic review of 28
studies concluded that the risk of cardiovascular disease in SLE
patients is at least double compared with the general population, and is
one of the major causes of death (Manger et al., 2002; Schoenfeld
et al., 2013). Male SLE patients also have nearly a 4-fold increased
risk of cardiovascular disease compared to females (Pons-Estel et al.,
2009; Urowitz et al., 2010). The most common cardiac complication
of SLE is pericarditis (Box 1) (Buppajamrntham et al., 2014),
followed by myocarditis (Thomas et al., 2017), which may develop
into dilated cardiomyopathy (Box 1) and heart failure (Eriksson and
Penninger, 2005). While the exact pathogenesis of SLE-associated
pericarditis is still being explored, Bidani et al. demonstrated the
deposition of immunoglobulin (Ig), complement C1q and
complement C3 (Box 1) in pericardial vessel walls, accompanied by
mononuclear cell infiltration (Bidani et al., 1980). SLE-associated
myocarditis is likely mediated by immune-complex deposition, which
leads to complement activation, inflammation and myocardial injury
(Jain and Halushka, 2009). Up to 70% of SLE patients have a valvular
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abnormality, the most common being left-sided valve thickening and
regurgitation (Box 1) (Omdal et al., 2001; Jensen-Urstad et al., 2002).
Approximately 10% of SLE patients develop valvular disease from
Libman–Sacks endocarditis (Box 1) (Moyssakis et al., 2007). SLE is
also associated with an increased risk of coronary artery disease
(CAD), which is linked to inflammation and endothelial dysfunction
(Jain andHalushka, 2009).We discuss below the cardiac phenotyping
data available for inducible, spontaneous and engineered mouse
models of SLE. A decision tree to facilitate model choice is presented
in Fig. 3.
Inducible SLE models
Mice that develop graft-versus-host disease (GvHD) induced by
semi-allogeneic (Box 1) cell transfer are a classical inducible SLE
model for which information on cardiac effects is available.
Researchers recently developed another SLE model, in which the
TLR-7 agonist resiquimod (R-848) induces autoimmunity as a result
of severe systemic inflammation and tissue damage. Although the
pristane (Box 1)-induced-autoimmunity mouse model (Satoh and
Reeves, 1994) is a classical model of both SLE and RA, we do not
discuss it in this Review due to the lack of cardiac involvement data.
GvHD
In the ‘parent into F1’ GvHD model, parental donor T cells are
transferred into semi-allogeneic F1 recipients, causing the donor T
cells to react to host alloantigens (Box 1) (Perry et al., 2011).
Chronic GvHD progresses to systemic autoimmunity and most
prominently affects the skin, liver and intestine (Via, 2010).
Strikingly, while the heart does not appear grossly affected, T
cells do infiltrate the heart and the cardiac T cell repertoire replicates
that of affected organs, such as the intestine and the liver (Schilbach
et al., 2004). Histological examination of the heart in chronic GvHD
mice showed ‘Quilty-like’ lesions (Box 1) in the endomyocardium
(Schilbach et al., 2007), which indicate infiltration of long-lived
lymphocytes (Dong et al., 1997). Unlike in the intestines, however,
no evidence of immune-mediated tissue destruction was observed in
the hearts, despite increased expression of inflammatory cytokines.
The presence of cardiac CD8α+CD11c+ dendritic cells (DCs)
around the ‘Quilty-like’ lesions in the heart, but not in the intestine,
has been suggested as a reason for this striking difference.
CD8α+CD11c+ DCs inhibit the induction of inflammatory T cell
responses (Winkel et al., 1997; Fallarino et al., 2002) and may thus
prevent cardiac tissue destruction. Additional information on the
cells and the factors involved in protecting the heart in these GvHD
models would provide a crucial starting point to understand which
tissue microenvironment conditions lead to the breakdown of this
DC-mediated protection.
Resiquimod
TLR-7 activation via epicutaneous treatment with the TLR-7
agonists imiquimod or resiquimod induces SLE-like systemic
autoimmune disease in mice of different genetic backgrounds
(Yokogawa et al., 2014). This is in line with the observation that
altered TLR signalling and interferonopathy contribute to the
development of SLE in human patients and murine models
(Christensen and Shlomchik, 2007; Ewald and Barton, 2011).
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Fig. 1. Heart structures and their involvement in systemic autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis
(RA) and systemic sclerosis (SSc). Numbers in the table indicate frequency of the manifestation in each disease as reported in the literature cited in
this article. *, detected clinically due to patient presenting with symptoms; **, detected at post-mortem investigation in asymptomatic patients; +, presence reported
without information available on exact incidence; nd, information not available in cited literature; RV, right ventricle; LV, left ventricle.
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Box 1. Glossary
Alloantigens: any antigen that is present only in some individuals of a
species. Alloantigens stimulate the production of antibodies in individuals
that do not have this antigen.
Anichkov/Anitschkow cells: enlarged mononuclear cells with ovoid
nuclei, which are found in Aschoff bodies in inflamed hearts.
Anti-La antibodies: a type of anti-nuclear antibody, also called anti-
Sjögren’s-syndrome B (SSB) antibodies, associated with SLE and
Sjögren’s syndrome. Presence of anti-La antibody during pregnancy is
correlated with congenital heart block.
Anti-nuclear antibodies (ANAs): autoantibodies against nuclear material,
which is a hallmark of autoimmune diseases such as systemic lupus
erythematosus (SLE).
Anti-Ro antibody: a type of anti-nuclear antibody, also called anti-Sjögren’s-
syndrome A (SSA) antibodies, targeting the self-proteins Ro60 and/or Ro52.
They are commonly found in SLE and rheumatoid arthritis (RA).
Anti-Smith antibody: a type of anti-nuclear antibody against small nuclear
ribonucleoproteins (snRNPs). Specific for SLE.
Anti-topoisomerase-1/Scl70 autoantibodies: anti-topoisomerase, also
known as scleroderma antibody or anti-Scl-70 antibody, is an anti-nuclear
antibody that targets self-DNA topoisomerase 1, commonly found in
patients with autoimmune diseases such as systemic sclerosis (SSc).
Aschoff bodies/nodules: nodules of cellular infiltrate, connective tissue
and dead heart cells found in the hearts of patients with rheumatic fever.
Autoantibodies: antibodies directed against the individual’s own antigens.
Autoimmune glomerulonephritis: an autoimmune inflammatory disease
that affects the kidney by damaging the glomeruli or the blood vessels in the
kidneys, often a symptom in SLE.
Bony ankylosis: immobility or stiffness of a joint caused by the loss of
articular cartilage, often associated with greater severity of RA.
Cardiac valvulitis: inflammation of the heart valves.
Cardiomegaly: enlargement of the heart.
Complement C3: the complement system is a key part of innate immunity
and comprises numerous proteins that aid the removal of foreign or
damaged cells. The hydrolysis of complement protein C3 can lead to a
cascade of events that enhance opsonisation. An alternative pathway
resulting from C3 cleavage allows the cleavage of downstream complement
protein C5, which leads to recruitment of immune cells, an increase in
vascular permeability and formation of membrane attack complex (MAC),
causing target cells rupture.
Diffuse disease: a general term to describe diseases that are not occurring
in a specific location (focal); rather, it involves a larger area.
Dilated cardiomyopathy: a cardiac condition where the pumping
efficiency of the heart has decreased because the muscle layer of the
heart is stretched and thinned.
Effusion: the build up of excess fluid in the chest or the lungs that can cause
breathing difficulties and chest pain.
Emphysema-like lung pathology: emphysema is a member of a group of
lung diseases called chronic obstructive pulmonary disease (COPD), which
manifests itself as a shortness of breath. The elastic tissue in the lung is
compromised; therefore, the air sacs in the lungs of these patients are over-
inflated during inhalation. Furthermore, the bronchioles of the lungs also
collapse, making gas exchange more challenging. Damage to capillaries of
the lungs also reduces blood flow, making it more difficult to receive oxygen.
Fibrillin 1: an extracellular matrix glycoprotein and an essential component
of microfibrils, which are found in both elastic and rigid structures (e.g. blood
vessels, muscles and bones).
Fibrinoid: fibrinoid is a fibrin-like structure that is formed in the walls of
vessels and connective tissues.
Focal haemorrhage: bleeding in a confined and specific location.
Fractional shortening: a measure of the contractility of the heart.
Measured by the fraction of reduction of diastolic (maximum relaxation)
dimension that occurs at systole (maximum contraction).
Freund’s complete adjuvant (FCA): the water-in-oil adjuvant comprises
heat-killed Mycobacterium tuberculosis in paraffin oil and mannide-mono-
oleate. Used to boost the immune response at the site of antigen deposition
to ensure efficient vaccination.
Glomerular mesangial thickening: the mesangium is the structure
between the vessels inside the kidney glomerulus, surrounding capillaries
and smooth muscle cells of the arterioles. Thickening of this layer is
associated with membrano-proliferative glomerulonephritis, a type of kidney
disease common in SLE and RA.
Granuloma: localised nodular inflammations formed by immune cells
walling off foreign substances or areas of necrotic tissue.
Hydroxychloroquine (HCQ): orally administrated pharmaceutical
treatment for RA and SLE that changes the pH in lysosomes, thus
suppressing immune cell function.
Hyperplasia: enlargement in tissue size due to an increase in cell
proliferation, resulting in a higher than normal cell number.
Interstitial and perivascular fibrosis: in the heart, interstitial fibrosis refers
to the accumulation of collagen in the spaces between cardiomyocytes, while
perivascular fibrosis indicates fibrosis around a blood vessel in the heart.
Libman–Sacks endocarditis: a form of endocarditis associated with SLE.
Endocarditis is the inflammation of the inner layer of the heart, often also the
mitral valve. The disease causes lesions (vegetations) in the tissue and
haematoxylin bodies containing autoantibodies and degraded nuclear
material.
Lymphadenopathy: enlarged lymph node.
Major histocompatibility complex (MHC) class II I-Ag7 and I-Aq
haplotypes: haplotype refers to the specific variation of a set of genes
that are inherited together. A heterozygous individual will have two MHC
haplotypes, one from each parent. In mouse, various MHC class II
haplotypes exist: I-Ab, I-Ad, I-Ap, I-Aq, I-Ak, I-Ar, I-Af, I-As and I-Ag7.
Microangiopathy: also known as microvascular disease; a disease of
small blood vessels that can occur throughout the body.
Monoclonal gammopathy: a condition in which plasma cells produce an
excess amount of monoclonal protein (M protein). M proteins are fragments
of immunoglobulin generated by the abnormal proliferation of a plasma cell,
generating clones of the same structure and therefore affinity to a particular
epitope. This causes a shift in the size distribution of antibodies and can
impair immune function.
Monocytosis: elevated monocyte levels in the blood.
Myocardial angiostatin: angiostatin is an angiogenesis inhibitor that
blocks vessel growth; works by hindering endothelial cell proliferation.
Pannus: a fibrovascular structure that covers tissue in response to
inflammation. It consists of macrophages, fibroblast-like mesenchymal
cells and cells that secrete collagenolytic enzymes. Commonly found over a
joint (in RA) or cornea.
Pericarditis: inflammation of the pericardium, the fibrous membrane that
surrounds the heart.
Polyarthritis: an inflammatory disease in which at least five joints are
affected simultaneously.
Pristane: a mineral oil originally derived from shark liver oil. Now, it can be
synthesised, and the hydrocarbon compound is commonly used as an
adjuvant for inducing tumours, arthritis and lupus nephritis in rodent models
by stimulating antibody production.
Quilty-like lesions: tissue lesions that suggest the infiltration of long-lived
lymphocytes into the endomyocardium, commonly found in allogeneic
cardiac grafts.
Regurgitation: leakage or reverse flow of blood through the valves into the
heart due to valve disease.
Rheumatic carditis: a side effect of acute rheumatic fever, which is a
systemic inflammatory disease that causes the body to react to cardiac self-
antigen, causing inflammatory lesions in the heart.
Rheumatoid factors (RFs): antibodies that target the Fc portion of
immunoglobulin (Ig)G, often found in the blood of patients with RA.
Semi-allogeneic: allogeneic describes cells or tissue from a genetically
different origin of the same species. Semi-allogeneic denotes individuals
that share some genetic information, such as parents and offspring.
Splenomegaly: enlargement of the spleen.
Synovial inflammation: inflammation of the synovialmembrane in the joints.
Thrombosis: formation of a blood clot in a blood vessel.
Thymic atrophy: the decrease in size of the thymus, a primary lymphoid
organ crucial for T cell maturation in early life. The size of the
thymus reduces with age naturally, where the stroma is replaced with fat
tissue. As a hallmark of immune system senescence, thymic atrophy is
related to impaired resistance to infection and increased susceptibility to
cancer.
Vasculitis: inflammation of blood vessels that leads to their destruction.
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Our group recently used resiquimod to induce autoimmune
disease in CFN mice (a strain obtained by crossing C57Bl6/J, FVB/
NJ and NOD/ShiLtJ parental mice). We characterised cardiac
disease and found a striking phenotype progressing from acute
myocarditis to dilated cardiomyopathy (Hasham et al., 2017).
Resiquimod-treated CFN mice developed dilated cardiomyopathy,
and histopathological analysis revealed inflammatory damage to
the cardiac tissue, especially in the endocardium, myocardium
and papillary muscles, with features that resemble autoimmune
pancarditis. Furthermore, we found increased levels of IgG2a and
IgG2b autoantibodies against cardiac myosin and troponin. Both
IgG2a and IgG2b have been associated with pathological immune
responses in autoimmune disease (Ehlers et al., 2006). The
resiquimod model therefore seems a time- and resource-efficient
model to study cardiac involvement in systemic autoimmunity.
Spontaneous SLE models
BXSB, Murphy Roths Large (MRL/1) and New Zealand black
(NZB)×New Zealand white (NZW) (NZB/W) F1 mice
spontaneously develop SLE-like disease manifestations (Celhar
and Fairhurst, 2017). Importantly, all three strains also develop
immune-complex-mediated lesions in coronary vessels and have an
increased incidence of spontaneous myocardial infarcts (MIs).
Infarcted areas are characterised by cardiomyocyte necrosis, focal
haemorrhage (Box 1), leukocyte and macrophage infiltration, and
scar tissue formation. IgG and complement C3 deposits were found
in the vessels of both the atria and ventricles of all three strains,
leading to the conclusion that immune-complex deposition plays a
role in the underlying pathogenesis (Accinni and Dixon, 1979).
NZB/W
NZB/W F1 mice, obtained by breeding NZB females with NZW
males, spontaneously develop SLE-like nephritis, haemolytic
anaemia and classical SLE autoantibodies (Monneaux et al., 2001).
The cardiac phenotype of NZB/W mice has been thoroughly
characterised and they are currently considered the gold standard for
preclinical cardiac studies in SLE (Celhar and Fairhurst, 2017).
Lesions containing Anichkov cells (Box 1) are evident in the
epicardium, myocardium and endocardium from 4 months of age.
Epicardial lesions consist of focal regions of mononuclear cell and
neutrophil infiltrates, while myocardial lesions result from a more
chronic inflammatory process and consist of mononuclear cell
infiltrates and focal necrosis of myofibres. In the endocardium, both
the subendocardial tissue and heart valves are affected, and the
inflammatory lesions consist of mononuclear infiltrates, fibrinoid
deposition and hyperplasia (Box 1). The valve leaflet is thickened
and there is also evidence of fibrotic changes (Pansky and Freimer,
1974). Two recent studies used NZB/W F1 mice to assess the
therapeutic benefit of hydroxychloroquine (HCQ; Box 1) in SLE.
Long-term treatment resulted in reduced hypertension, reduced
endothelial dysfunction, and less damage to the heart and kidneys.
However, anti-dsDNA antibody levels remained unchanged,
reflecting no change in SLE disease activity (Gomez-Guzman
et al., 2014; Virdis et al., 2015). This suggests that the protective
effects of HCQ are not related to blocking autoantibody-mediated
damage, but a consequence of other mechanisms, such as decreased
production of reactive oxygen species (ROS) and increased nitric
oxide bioavailability (Meng et al., 1997; Gomez-Guzman et al.,
2014). However, despite not targeting anti-dsDNA antibodies, the
Target organ: heartAutoimmune patient Animal model
- SLE
- RA
- SSc
- Spontaneous
- Inducible
- Engineered 
Symptoms:
- Systemic inflammation 
  (e.g. elevated IFN- levels)
- Auto-antibodies (e.g. ANAs)
- Systemic and organ-specific
  tissue damage (e.g. vasculitis,
  nephritis)
Cardiac phenotypes:
- Inflammation
- Cardiac fibrosis and valve
  thickening
- Remodelling and heart failure
- Cardiomyocyte dysfunction
- Endothelial dysfunction
- Arrythmias
Model phenotypes:
- Myocarditis and dilated
  cardiomyopathy (e.g. R-848, PD-1−/−)
- Valvulitis (e.g. TTP−/−, NZB/NZW)
- Micro-angiopathy (Fra-2)
- Myocardial infarcts (e.g. 
   BXSBNZB)
Immune-mediated
damage Animal model
New therapies
Experimental
immune-mediated
damage
Fig. 2. Systemic autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and systemic sclerosis (SSc) cause
immune-mediated damage to the heart, which may manifest as acute inflammation, fibrosis, valve disease, remodelling towards heart failure,
endothelial and cardiomyocyte dysfunction or arrhythmias. To study selected or combined cardiac phenotypes, the research community benefits from awide
range of spontaneous, inducible and engineered mouse models, which allow mechanistic studies to improve our understanding and identify targets for new
therapeutic approaches. IFN-γ, interferon gamma; ANAs, anti-nuclear antibodies; R-848, resiquimod; PD-1−/−, programmed cell death 1 knockout mice; TTP−/−,
tristetraprolin knockout mice; Fra-2, fos-related antigen 2 transgenic mice.
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HCQ-mediated positive effects on endothelial dysfunction may
make HCQ a useful future therapeutic to improve cardiac
complications in SLE patients.
BXSB
BXSB mice are derived from a cross between a C57BL/6J female
and a SB/Le F1 male (Murphy and Roths, 1978; Theofilopoulos
and Dixon, 1981; Maibaum et al., 2000). They spontaneously
develop an SLE-like disease including lymph node hyperplasia,
immune-complex-mediated (autoimmune) glomerulonephritis
(Box 1), thymic atrophy (Box 1), monocytosis (Box 1), elevated
immunoglobulin concentrations associated with monoclonal
gammopathy (Box 1), and moderately elevated ANAs and anti-
ssDNA and anti-dsDNA antibodies (Theofilopoulos and Dixon,
1981). Notably, males show accelerated disease onset due to the
mutant Y-linked autoimmune accelerator (Yaa) locus (Fossati et al.,
1995). At necropsy, 15-30% of BXSB mice were found to have
experienced a previous and/or acuteMI that involved both ventricles
and was extensive enough to be a possible contributing factor to
death (Accinni and Dixon, 1979). However, this study currently
appears to be the only one exploring cardiac involvement in this
model.
SLE cardiac phenotype
Neutrophils Anichkov
cells
T cells/
long-lived
lymphocytes
Auto-
antibodies
C3 Valvular
disease
Cardiac
lesions
Vascular
damage
Carditis MI Dilated
cardiomyopathy
Cellular
phenotype
Tissue
phenotype
Adaptive
immunity
Innate
immunityComplement Valves Muscle Vessels
RV LV
BXSB
NZB/W
NZB/W GvHD
PD-1−/−
NZB/W R-848
PD-1−/−
PD-L1−/−
BXSB
BXSBNZB
NZB/W GvHD
NZB/W
BXSBNZW
R-848
PD-1−/−
PD-L1−/−
R-848
PD-1−/−
PD-L1−/−
BXSBNZWBXSB
BXSBNZW
Faslpr & Faslgld
(i)    T cell repertoire resembles that of intestine and liver
(ii)   Lesions in endomyocardium
(iii)  Infiltration of long-lived lymphocytes in myocardium
(iv)  Cardiac CD8+CD11c+ DCs may inhibit Th1 responses
Schilbach et al., 2004
Schilbach et al., 2007
Dong et al., 1997
Winkel et al., 1997; Fallarino et al., 2002
GvHD
R-848In
du
ci
bl
e
(i)    Cardiac tissue damage as assessed by histology
(ii)   Dilated cardiomyopathy in CFN mice
(iii)  Increased level of anti-cardiac troponin/myosin autoantibodies
Yokogawa et al., 2014; Hasham et al., 2017
Hasham et al., 2017
Hasham et al., 2017
Sp
on
ta
ne
ou
s
NZB/W
BXSB
(i)    Presence of Anichkov cells
(ii)   Anti-DNA autoantibodies
(iii)  Chronic inflammation induces lesions and infiltration of neutrophils 
       and mononuclear cells
(iv)  Inflamed and fibrotic heart valves
(v)   IgG and complement C3 deposits in atrial and ventricle vessels
Pansky and Freimer, 1974
Accinni and Dixon, 1979
Pansky and Freimer, 1974
Pansky and Freimer, 1974
Pansky and Freimer, 1974
(i)   15-30% of mice had previous or acute MI at necropsy
(ii)   IgG and complement C3 deposits in atrial and ventricle vessels 
Theofilopoulos and Dixon, 1981
Accinni and Dixon, 1979
BXSBNZB
(i)    Majority of males had MI and myocardial lesion at autopsy
(ii)   Degenerative coronary vascular diseases associated with MI
(i)    Dilated cardiomyopathy and fatal myocarditis
(ii)   Anti-troponin autoantibodies and dilated cardiomyopathy 
Faslpr/Faslgld (i)    Age-dependent increased MI incidence in males
PD-1−/−
PD-L1−/−
En
gi
ne
er
ed
(i)    Dilated cardiomyopathy on MRL background
(ii)   Myocarditis and congestive heart failure at 2-3 months
Hang et al., 1981
Hang et al., 1981
Yoshida et al., 1987
Wang et al., 2010; Okazaki et al., 2003
Okazaki et al., 2003
Nishimura and Honjo, 2001
Lucas et al., 2008
Fig. 3. Cardiac phenotypes in mouse models of systemic lupus erythematosus (SLE).We include a decision tree to aid model choice based on the cellular
mechanisms or tissue effect of interest, with a summary of the cardiac information available for each model. C3, complement-component 3 protein; GvHD, graft-
versus-host disease; PD-1, programmed cell death 1; PD-L1, programmed death-ligand 1; R-848, resiquimod; lpr, lymphoproliferation; gld, generalized
lymphoproliferative disease; DCs, dendritic cells; Th1, T-helper cell type 1; MI, myocardial infarction; RV, right ventricle; LV, left ventricle; MRL, Murphy Roths
Large.
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BXSB×NZW
A hybrid model of BXSB males and NZW females shows an
SLE phenotype including autoantibody production, circulating
immunoglobulin-bound glycoprotein gp70 immune-complexes, and
deposition of immunoglobulin and gp70 in glomeruli. Male F1
offspring develop a disease resembling the accelerated SLE phenotype
that occurs in BXSB males (Hang et al., 1981).
The majority of these mice show degenerative coronary vascular
disease associated with MI, with most males exhibiting myocardial
lesions at necropsy. The disease showed delayed onset and oestrogen
dependence in females, and necropsy revealed infarcts in only one
third of females. The majority of vascular and myocardial lesions
occurred in the right ventricle, right atrium and left subendocardium
(Yoshida et al., 1987). However, coronary disease in BXSB×NZW
mice does not seem to be immune-complex-mediated or associated
with thrombosis (Box 1), as the vascular lesions did not present with
an inflammatory response (Hang et al., 1981).
Faslpr (lpr) and Faslgld (gld)
Lymphoproliferation (lpr) and generalized lymphoproliferative
disease (gld) mice carry defects in the apoptosis-mediating cell-
surface molecule Fas and its ligand, Fasl, respectively. These mice
develop lymphadenopathy (Box 1) because of an age-dependent
accumulation of non-malignant CD4–CD8− T cells in peripheral
lymphoid organs. The Faslgld strain was discovered as an autosomal
recessive mutation in C3H/HeJ mice (Roths et al., 1984). The Faslpr
mutation was discovered during inbreeding of MRL/Mp mice
derived from crosses between several parental strains – the LG/J
strain with minor contributions from C3H/Di, C57BL/6 and AKR/J
(Theofilopoulos and Dixon, 1985). TheMRL/Mp background itself
carries a normal Fas gene but still develops an SLE-like
autoimmune disorder later in life (Perry et al., 2011).
While the heart remains largely unaffected in MRL-Faslpr mice
(Theofilopoulos and Dixon, 1981), there seems to be an age-
dependent increase in MI incidence in males, albeit at lower rates
than in BXSB×NZW mice (Yoshida et al., 1987).
Engineered SLE models
A variety of engineered mouse models exhibit phenotypes similar
to selected SLE manifestations. Notably, most of these models
were not developed with the intention to induce autoimmunity.
However, any disruption of pathways involved in the resolution of
inflammation and feedback inhibition has the potential to cause
aberrant immune activation and autoimmunity. The most relevant
model with both an autoimmune and cardiac phenotype is based on
the disruption of the programmed cell death-1 (PD-1)/PD-1 ligand 1
(PD-L1) axis.
PD-1 and PD-L1
PD-1 and its ligand, PD-L1, are potent negative regulators of T cell
activation. They have been implicated in various autoimmune
conditions and have recently obtained notoriety due to their clinical
use in cancer therapy. Despite their success in oncology, PD-1
checkpoint inhibitors have also caused severe cardiac side effects
such as myocarditis (Varricchi et al., 2017). Importantly, PD-L1 is
expressed in cardiac tissue (Nishimura and Honjo, 2001). While
disruption of PD-1/PD-L1 signalling induces SLE-like autoimmune
disease with dominant cardiac involvement (Nishimura and Honjo,
2001; Nishimura et al., 2001), the relative contributions of the direct
effects of PD-L1 depletion in the heart versus the indirect effects
mediated by systemic autoimmunity are not yet understood and need
to be carefully considered.
PD-1 deficiency in mice causes dilated cardiomyopathy, which is
correlated with autoantibodies against cardiac troponin I, and the
development of fatal myocarditis (Wang et al., 2010; Okazaki et al.,
2003).
PD-L1-deficient mice develop dilated cardiomyopathy (Nishimura
and Honjo, 2001). A particularly interesting study investigated PD-L1
depletion in the autoimmune-proneMRL-Faslpr background. Survival
of PD-L1−/−MRL-Faslpr mice was significantly decreased compared
to the MRL-Faslpr controls. While MRL-Faslpr mice develop
lymphadenopathy, splenomegaly (Box 1), skin lesions and fatal
renal disease at around 5-6 months of age, PD-L1−/− MRL-Faslpr
mice developed congestive heart failure resulting from autoimmune
myocarditis as early as 2-3 months of age. Histopathological analysis
revealed pancarditis spanning the endocardium, myocardium,
epicardium, atria and both ventricles. Macrophages, followed by T
cells, accumulated in the hearts and high titres of autoantibodies
against cardiacmyosin and cardiac troponin I were present at 2 months
of age. Autoantibodies were detected only when overt disease was
present, suggesting that they may not be involved in the initial
development of heart disease, and titres of anti-dsDNA autoantibodies
were not increased over control levels. Notably, PD-L1−/− mice on
both the MRL+/+ and MRL-Faslpr background developed a very
similar degree of myocarditis, showing that the Faslpr mutation does
not have a role in the development of autoimmune-mediated heart
disease under these conditions (Lucas et al., 2008).
Rheumatoid arthritis
RA is a systemic autoimmune disorder characterised by synovial
inflammation (Box 1), autoantibody production, and destruction of
bone and cartilage. Systemic features of RA include cardiovascular,
pulmonary, skeletal and psychological complications. RA is more
common in women, and is associated with genetic and environmental
risk factors (McInnes and Schett, 2011). Rheumatoid factors (RFs;
Box 1) were the first type of autoantibody described to be associated
with RA (Waaler, 1940) and their presence is used as a diagnostic
biomarker (Whiting et al., 2010). They target the Fc region of IgG in
immune-complexes and, under healthy conditions, serve an important
physiological function through facilitating and clearing immune-
complexes. In RA, RF-mediated enhancement of immune-complex
formation potentiates the arthritogenicity of other pathological
autoantibodies, including anti-citrullinated protein antibodies
(ACPAs) (Van Snick et al., 1978; Pope et al., 1974). ACPAs are
IgG autoantibodies that self-aggregate into immune-complexes,
activate complement, stimulate inflammation and cause chronic
synovitis (Silverman and Carson, 2003). IgG immune-complexes also
recruit T cells, thus perpetuating RA (Lang et al., 1999).
Patients with RA are 30-60% more likely to suffer from
cardiovascular disease compared to the general population, and this
complication accounts for around half of all deaths in RA (Han et al.,
2006; Avina-Zubieta et al., 2008). Furthermore, male patients with
RA are significantly more likely to suffer from a cardiovascular event
compared to female patients (Naranjo et al., 2008). One of the most
common cardiac manifestations in RA is pericardial inflammation
(Fig. 1), which is also a prognostic indicator of the severity of this
autoimmune disease (Voskuyl, 2006). RA also increases the risk of
vascular disease by causing changes in lipid handling (Maradit-
Kremers et al., 2005) and instigating vasculitis (Box 1) in coronary
vessels (Voskuyl, 2006), culminating in a higher incidence of
asymptomatic ischemia and MI (Maradit-Kremers et al., 2005). The
immunological mechanisms underlying the cardiac manifestations of
RA are mostly attributed to the chronic inflammation with increased
c-reactive protein (CRP), TNF, IL-1 and IL-6. A more atherogenic
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lipid profile with less-efficient high-density lipoprotein (HDL)
cholesterol, and paradoxically fewer and smaller but denser and
more pathological low-density lipoprotein (LDL) cholesterol, is
prevalent (Castañeda et al., 2016) and accounts for a higher risk of
ischemic cardiac disease. There may also be a degree of shared
inflammatory mediators between joint inflammation and the extra-
articular manifestations of RA. For example, ACPA targets, such as
vimentin, enolase and fibronectin, are also present in the myocardium
(Giles et al., 2012). Rheumatoid granulomas (Box 1) can accumulate
in any organ, including the heart, and their location determines
the related functional impairment (Voskuyl, 2006). Chronic
inflammation also triggers the deposition of acute-phase protein
amyloid, which can cause a range of pathologies, including
conduction defects, cardiomegaly (Box 1), cardiomyopathy and
heart failure (Voskuyl, 2006; Kuroda et al., 2006). The cardiac
phenotyping data available for inducible, spontaneous and
engineered mouse models of RA is discussed below. A decision
tree to facilitate model choice is presented in Fig. 4.
Inducible RA models
Immunisation with collagen is a common way to induce
experimental RA. It is also the only inducible RA mouse model
with any, albeit little, information available on potential cardiac
involvement.
Collagen-induced arthritis (CIA)
Murine CIA closely resembles human RA, and develops upon
immunisation with type II collagen in Freund’s complete adjuvant
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Fig. 4. Cardiac phenotypes inmousemodels of rheumatoid arthritis (RA).We include a decision tree to aid model choice based on the cellular mechanisms or
tissue effect of interest, with a summary of the cardiac information available for each model. C3/C5, complement-component 3/5 protein; IIJ, inherited inflamed
joint; IL-6, interleukin-6; TTP, tristetraprolin; TNF, tumour necrosis factor; CIA, collagen-induced arthritis; iNOS, inducible nitric oxide synthase overexpression.
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(Box 1) (Courtenay et al., 1980; Asquith et al., 2009). Features of
CIA include polyarthritis (Box 1), which is characterised by
synovial hyperplasia, inflammatory infiltration, and cartilage and
bone erosion. The development of CIA is related to B and T cell
responses, including collagen-specific T cells and anti-collagen
type II antibodies of the IgG2 isotype (Asquith et al., 2009).
Studies on the heart in CIA are rare and have focused on vascular
effects. One study found that CIA increased inducible nitric oxide
synthase (iNOS) expression in the aorta and in cardiac myocytes
(Palma Zochio Tozzato et al., 2016), and a separate study reported
endothelial contractile dysfunction (Reynolds et al., 2012). Given
that the CIA model reproduces the underlying autoimmune
mechanisms of human RA, these observations may reflect the
vascular and cardiac changes that occur in RA patients, with studies
also showing that iNOS expression contributes to endothelial
dysfunction (Mäki-Petäjä et al., 2008).
Spontaneous RA models
BALB/c ZAP-70W163C mutants (SKG)
SKG mice harbour a spontaneous mutation in the protein kinase
ZAP-70, which causes self-reactive T cells to escape negative
selection in the thymus, thereby leading to T cell-mediated arthritis
(Rothe et al., 2017; Guerard et al., 2016b). The arthrogenicity of the
ZAP-70 mutation seems independent of genetic background
(Guerard et al., 2016a). However, different environmental
conditions, such as variation in the microbiome, might change the
extra-articular manifestations (Rehaume et al., 2014). At baseline,
SKG mice have increased numbers of cardiac neutrophils and
monocytes/macrophages. Following MI, researchers observed a
further 6-fold increase in infiltrating neutrophil numbers and a
persistently high Ly-6C+ macrophage infiltrate (Hsieh et al., 2017).
The change in the number and phenotype of cardiac immune cells is
likely to negatively influence cardiac repair and ventricular
remodelling, leading to worse outcomes. This is corroborated by
the role of excessive numbers of infiltrating neutrophils in mediating
tissue damage in patients post-MI (Carbone et al., 2013).
Bone phenotype spontaneous mutation 1 (BPSM1)
BPSM1 mutant mice carry a spontaneous mutation in the Tnf gene,
which leads to constitutive overexpression of tumour necrosis factor
(TNF) (Lacey et al., 2015). Excess levels of inflammatory
cytokines, including TNF, are known to mediate RA pathogenesis
(Parameswaran and Patial, 2010; Sakkou et al., 2018).
BPSM1 C57BL/6 mice develop polyarthritis and heart valve
disease accompanied by aortic regurgitation and inflammation of
the mitral valve (Lacey et al., 2015). Thus, these mice may be an
interesting model to study the role of TNF in immune-mediated
heart disease.
Inherited inflamed joints (IIJ)
The IIJ strain was developed by crossing an SJL/J wild-type male
mouse that had spontaneously developed arthritis (Waldner et al.,
2000) to SJL/J females. IIJ mice develop bone and cartilage
erosion, synovial hyper-proliferation and immune cell infiltration
in distal joints. The model also shows increased IL-6 and elevated
serum antibody levels with systemic inflammation of multiple
organs. This includes mild cardiac involvement, which was
detected histologically. However, unlike in human RA patients,
joint pathology is asymmetric and it remains to be determined
whether the B cell expansion and the presence of IgG support the
notion that the IIJ mouse truly models autoimmunity (Adipue
et al., 2011).
Engineered RA models
A variety of engineered mouse models show RA-associated
phenotypes and have been valuable in the investigation of
causative mechanisms ranging from antigen-specific adaptive
T cell responses (the K/BxN and TS1×HACII mice) to increased
systemic cytokine levels [in tristetraprolin (TTP)−/− and gp130F759
mice]. Heart involvement has been described for the K/BxN model,
but information for cardiac phenotypes in TS1×HACII mice is not
available.
K/BxN T cell receptor (TCR) transgenic
K/BxN mice were generated by crossing the TCR transgenic KRN
line with NOD mice expressing the major histocompatibility
complex (MHC) class II molecule Ag7 (Box 1) (Kouskoff et al.,
1996). In these mice, T cells recognise glucose-6-phosphate
isomerase (GPI) self-peptides presented by Ag7. This activates
GPI-reactive B cells, which leads to the production of anti-GPI
autoantibodies, causing arthritis (Matsumoto et al., 1999). The
model shares many clinical, histological and immunological
features of human RA, and its earliest phenotypic manifestation is
joint swelling at around 3 weeks of age. Other features include
symmetrical articular involvement, leukocyte infiltration, synovitis,
pannus formation (Box 1), and cartilage and bone erosion followed
by remodelling and fibrosis. However, these mice do not have
elevated RF and develop high titres of anti-GPI autoantibodies
(Kouskoff et al., 1996; van Gaalen et al., 2004).
Several studies observed cardiac involvement in the K/BxNmodel.
This includes inflammation of the mitral valve (Binstadt et al., 2009;
Kaplan et al., 1964; Ziporen et al., 1996), and occasionally of the
aortic valve (Binstadt et al., 2009; Fraser et al., 1995), endocarditis
(Hobday et al., 2014), and myocardial Aschoff nodules (Box 1) and
Anichkov cells (Binstadt et al., 2009; Fraser et al., 1995).Mitral valve
inflammation correlated with complement C3 and Ig deposition as
seen in patients with rheumatic carditis (Box 1) or Libman–Sacks
endocarditis (Binstadt et al., 2009; Kaplan et al., 1964; Ziporen et al.,
1996).Mice developed endocarditis at as early as 3 weeks of age. The
inflammatory cells involved were mainly macrophages and T cells.
However, separate mechanisms have been implicated in joint
inflammation and endocarditis. While the initiation of both heart
and joint inflammation involves the TCR, Ag7 and B cells, further
progression of disease differs in their dependence on complement and
Fc receptors (Hobday et al., 2014; Binstadt et al., 2009; Fraser et al.,
1995). While complement C5 is required for disease progression in
the joints, endocarditis depends on Fc receptors and is independent of
C5. This suggests that autoantibodies binding to the mitral valve
might provoke inflammation via their interaction with activating Fc
receptors.
TS1×HACII
TS1×HACII transgenic mice express hemagglutinin (HA) driven by
an MHC class II promoter (and is thus expressed systemically by
antigen-presenting cells), as well as a TCR that recognises HA.
They develop spontaneous RA with symmetrical ankle and wrist
swelling, mononuclear lymphocytic infiltration, cartilage and bone
erosion, and pannus formation. The majority of the synovium-
infiltrating cells are neutrophils, with a few T cells. Disease
development in these mice is accompanied by inflammatory
cytokine production, systemic B cell activation and an enhanced
lymph node response. However, RA also develops in mice lacking
B cells, indicating that autoantibody production is not required for
disease initiation (Rankin et al., 2008). Heart involvement was also
determined upon initial phenotyping of these mice, with some
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animals developing cardiac valvulitis (Box 1) and myocarditis
(Rankin et al., 2008).
TTP−/− mice
TTP is an RNA-binding protein that has anti-inflammatory effects
via binding and destabilising Tnfa mRNA. This leads to TNF-
excess syndrome characterised by systemic inflammation. TTP−/−
mice exhibit autoimmunity and their phenotypic features include
arthritis, dermatitis, conjunctivitis, glomerular mesangial thickening
(Box 1), loss of adipose tissue and myeloid hyperplasia (Taylor et al.,
1996).
Mice as young as 7 weeks also develop aortic and left-
atrioventricular valvulitis, which is likely related to the greater
haemodynamic load in the left chambers. Some mice also exhibit
small multifocal myocardial lesions with mononuclear infiltrates.
Monocytes and granulocytes, but not lymphocytes, infiltrate the
valves. Other features include valve fibrosis, gross thickening,
elastic fibre disruption, collagen deposition and neovascularisation.
TTP−/−mice can also display left-ventricular and atrial enlargement
in both end-systolic and end-diastolic phases, consistent with left
ventricular overload and functional impairment of the mitral and
aortic valve. However, left-ventricular fractional shortening (Box 1)
and ejection fraction remain unaltered. The underlying pathogenesis
has been attributed to increased local TNF levels, presumably
produced by the infiltrating leukocytes. Notably, mice lacking TTP
and both TNF receptors also had mild valve-leaflet thickening and
cellular infiltration, suggesting that TTP may also cause TNF-
independent valve inflammation (Ghosh et al., 2010). However, the
valvular phenotype in these mice exhibits neither T nor B cell
infiltration, thus does not closely resemble valvular disease in
human RA, which is characterised by the presence of lymphocytic
granulomas (Iveson et al., 1975).
gp130F759 (F759)
The F759mouse line has been generated by targeted mutation to insert
mutant human IL6 carrying a tyrosine-to-phenylalanine substitution at
position 759 (Y759F) into the corresponding region of the mouse
gene. Y759F disrupts inhibitory SHP-2 signalling downstream of
interleukin-6 (IL-6), and F759 mice spontaneously develop age-
dependent chronic and progressive arthritis accompanied by
autoantibody production and T cell abnormalities from around
1 year of age. Histologic examination showed leukocytes infiltrating
the joint space, hyperplasia of the synovium with pannus formation,
cartilage and bone destruction, and bony ankyloses (Box 1) (Atsumi
et al., 2002).
IL-6 has been implicated as a cause of cardiac hypertrophy, and
an increase in IL-6 levels is a risk factor for sudden cardiac death in
patients with CAD (Hagiwara et al., 2007; Fisman et al., 2006).
Although the cardiac phenotype of the F759 mouse line has not
been studied yet, with increasing appreciation of the detrimental
effects of increased systemic levels of inflammatory cytokines on
the heart it might soon prove a valuable and relevant mousemodel to
study this aspect of heart disease.
SSc
SSc, also termed scleroderma, is a rare systemic autoimmune
condition associated with high mortality. Skin fibrosis is the
distinguishing hallmark of the disease, and microvascular damage
and generalised fibrosis in multiple organs are common (Allanore
et al., 2015; Denton and Khanna, 2017). The primary underlying
pathogenesis of the disease is thought to involve vascular injury,
triggering endothelial cell and platelet activation, endothelin-1 and
chemokine production, and increased expression of adhesion
molecules. This leads to the recruitment and infiltration of
inflammatory cells, including type 2 T helper cells (Th2),
macrophages, pDCs and autoantibody-producing B cells, among
others. Factors secreted from these cells, including TGF-β, IL-13
and IL-6, activate fibroblasts that can differentiate into
myofibroblasts, resulting in excess extracellular matrix (ECM)
production and fibrosis (Allanore et al., 2015). ANAs are present in
90% of patients, with the three major subclasses of autoantibodies in
SSc being anti-centromere, anti-topoisomerase (Topo)-1 (Box 1)
and anti-RNA polymerase III antibodies (Ho and Reveille, 2003).
While different ANA profiles are associated with different types of
SSc, anti-Topo-1 antibodies are the most common and are
associated with pulmonary fibrosis and cardiac involvement
(Hesselstrand et al., 2003).
These pathogenic processes in SSc, including diffuse lesions
(Box 1) in the micro- and macro-vasculature, immune dysfunction,
and fibrosis, damage the myocardium, endocardium, pericardium
and conduction systems of the heart (Fig. 1) (Ferri et al., 2005). As
such, a range of cardiac pathologies, including pericardial effusions
(Box 1), conduction defects, ischemia and hypertension may occur
(Kahan and Allanore, 2006; Agrawal et al., 2016). In the
myocardium, patchy distribution of myocardial fibrosis and
contraction band necrosis is pathognomonic of the disease
(Lambova, 2014). However, myocardial involvement in SSc is
distinct from atherosclerotic coronary disease as it may involve the
subendocardial layer, and hemosiderin deposits are absent
(Champion, 2008). Cardiac involvement is often underestimated
in SSc, yet accounts for up to one-third of the mortality among SSc
patients (Ferri et al., 2002; Steen and Medsger, 2000). While this
may be close to the 25% mortality due to cardiac events in the
general population, mortality in SSc patients occurs up to a decade
earlier (Belch et al., 2008).
Most currently available SSc models focus on fibrosis as the
dominant phenotype, but may not replicate the underlying
autoimmune aspect of the disease. The full range of available
models has been reviewed elsewhere (Artlett, 2014). For the purpose
of this Review, we considered which model may in fact have a
systemic inflammatory/autoimmune component and we focus on
those with established or potential immunological and cardiac
relevance. A decision tree to facilitate model choice is presented in
Fig. 5.
Inducible SSc models
Awide range of inducible mousemodels of SSc has been established,
the majority of which focus on fibrosis of the skin and lung as their
primary phenotypes. These models are based on different underlying
principles, including the induction of autoimmunity (e.g. the anti-
DNA Topo-I and GvHD models), tissue damage and inflammation
followed by fibrosis (e.g. the hypochlorous and bleomycin models),
or themodification of systemic hormone systems [e.g. the angiotensin
(Ang) II model].
Sclerodermatous GvHD
The primary inducible model used to study human SSc is chronic
GvHD, described above (see SLE section). Transfer of donor
splenocytes and/or bone marrow to recipients matched for MHC but
mismatched at loci encoding minor histocompatibility antigens
(Beyer et al., 2010; Jaffee and Claman, 1983; Zhang et al., 2002)
induces autoimmunity. A modified model based on the injection of
splenocytes into recipients deficient in mature T and B cells exhibits
all major components of human SSc, including dermal thickening,
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progressive fibrosis of internal organs, vasoconstriction and altered
expression of vascularity markers in skin and internal organs, early
immune activation, inflammation in skin and internal organs, and
the production of anti-DNA Topo I/Scl70 autoantibodies (Box 1)
(Ruzek et al., 2004).
When using chronic GvHD as an SSc model, researchers found
that the animals developed cardiomyopathy associated with
decreased capillary density in the myocardium, which is a
hallmark of microangiopathy (Box 1) in human SSc patients.
Increased perivascular inflammation due to infiltration of T cells
and monocytes has also been observed (Venalis et al., 2015).
DNA Topo-I immunisation
Autoantibodies against Topo I are a central feature of SSc and
correlate with dermal and pulmonary fibrosis, and, importantly,
with cardiac involvement (Hesselstrand et al., 2003). Immunisation
of mice with recombinant Topo I and Freud’s complete adjuvant
increased the levels of anti-Topo-I and other autoantibodies and
induced dermal sclerosis and pulmonary fibrosis (Yoshizaki et al.,
2011). Although there is no information available on cardiac
pathology in this model, it seems a promising candidate to
investigate cardiac involvement in SSc due to its underlying
autoimmune nature.
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Fig. 5. Cardiac phenotypes in mouse models of systemic sclerosis (SSc). We include a decision tree to aid model choice based on the cellular
mechanisms or tissue effect of interest, with a summary of the cardiac information available for each model. GvHD, graft versus host disease; Topo I, type I
topoisomerase; Tsk, tight skin; Ang II, angiotensin type II; Fra-2, fos-related antigen 2; uPAR, urokinase receptor.
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Bleomycin
Bleomycin is an antineoplastic antibiotic used in cancer
chemotherapy that can cause injury and fibrosis in the skin and
internal tissues of mice (Yamamoto et al., 1999, 2000). Cardiac
involvement in bleomycin-induced sclerosis has been investigated
primarily as a knock-on effect of pulmonary fibrosis and lung
pathology. Administration of bleomycin to induce pulmonary
fibrosis also causes right-ventricular hypertrophy (Hemnes et al.,
2008; Rathinasabapathy et al., 2018). Subsequent treatment with
sildenafil, a phosphodiesterase type 5 inhibitor used to treat
pulmonary arterial hypertension, decreased the degree of
pulmonary, vascular and right-ventricle fibrosis as well as the
associated cardiac hypertrophy. Notably, while the majority of
bleomycin-induced SSc studies focus on inducing fibrosis as their
main readout, bleomycin treatment does induce the release of
autoantibodies, most likely in response to tissue damage (Ishikawa
et al., 2009). It therefore remains to be established whether there is a
role of anti-heart autoimmunity in the bleomycin model and
whether this model is therefore suitable for investigating immune-
mediated heart phenotypes in SSc.
Angiotensin II
Ang II has been proposed as an SSc model due to its potent
fibrotic effect on the skin (Stawski et al., 2012). SSc patients have
elevated serum levels of Ang II (Kawaguchi et al., 2004), and
pharmacological inhibition of the Ang II receptor can ameliorate
fibrosis in mice (Murphy et al., 2015). Notably, however, Ang II is
the main effector of the renin-angiotensin system (RAS), which
is also a key regulator of blood pressure and cardiac function. It
is therefore also used in cardiovascular research to induce
hypertension, cardiac hypertrophy and fibrosis (Kim and Iwao,
2000).
While Ang II mice might be a useful model for questions related
to selected mechanisms and phenotypes in either SSc or
cardiovascular pathology, it is likely to be unsuitable as a model
for the heart disease that develops as a consequence of systemic
autoimmunity.
Spontaneous SSc models
The two main spontaneous mutations causing SSc-like
manifestations in mice are the tight skin (Tsk)1 and Tsk2
mutations (Green et al., 1976). Tsk1/+ mice harbour a mutation in
the fibrillin 1 (Fbn-1) gene (Box 1) (Siracusa et al., 1996), whereas
Tsk2/+ mice have a mutation in the collagen type III, alpha I
(Col3a1) gene (Long et al., 2014). Both mutations are homozygous
lethal, so mice need to be maintained as heterozygotes.
The tight skin-1 (Tsk1/+) mouse
Tsk1/+ mice exhibit skin, tendon and cardiac fibrosis, and
autoimmunity with extensive B cell activation and autoantibody
formation, but also develop phenotypes that differ from human
SSc, including hypodermal collagen accumulation (Baxter et al.,
2005) and an emphysema-like lung pathology (Box 1) (Rossi
et al., 1984). Tsk1/+ mice also lack several features of SSc such as
vascular injury and mononuclear cell infiltration (Pablos et al.,
2004), and show normal capillary density in myocardial tissue
without changes in perivascular inflammation (Venalis et al.,
2015).
Cardiac effects in Tsk1/+ mice were first reported in the original
description of the Tsk1/+ model, which showed cardiomegaly
most dominant in the atria (Green et al., 1976; Osborn et al., 1987).
Heart enlargement was accompanied by a shift in the ratio of
collagen I, II and III. In healthy hearts, collagen I accounts for 67%
of total collagen. In Tsk1/+ mice this increases to 95%. Notably,
the ECM isolated from the hearts of Tsk1/+ mice stimulates
endothelial cells to become fibroblasts, which indicates a pro-
inflammatory and fibrotic effect (Xu et al., 2011). Electron
microscopy of the left ventricle further revealed that
cardiomyocytes are present in a non-relaxed state, and showed
accumulation of perivascular and interstitial oedema fluid, and
isolated areas of cardiomyocyte necrosis (Box 1) (Osborn et al.,
1987). Tsk1/+ mice also have high levels of myocardial oxidative
stress, which increases myocardial angiostatin (Box 1) production
and inhibits endothelium-dependent vasodilation (Weihrauch
et al., 2007). Considering that ROS generation in human SSc
drives the differentiation of cardiac fibroblasts into
myofibroblasts, accounting for the increased production of ECM
proteins such as collagen I and the resultant fibrosis, parallels can
be drawn between this model and the human phenotype of SSc.
The hearts of Tsk1/+ males also have significantly more total
collagen than those of wild-type males (Manne et al., 2013).
Cardiac fibrosis in the Tsk1/+ mouse line was used to study the
effects of D-4F, an apolipoprotein A-I mimetic that improves
vascular function in SSc-related vascular problems affecting the
heart (Weihrauch et al., 2007). This study demonstrated that D-4F
treatment significantly reduces posterior-wall thickening,
highlighting a reduction in fibrosis. It was also found that IRF5 is
present in the hearts of untreated Tsk1/+ mice, which also had high
levels of apoptotic cells. D-4F treatment decreased IRF5 expression,
which could explain the reduction in inflammation and the reduced
number of apoptotic cells in the treated animals compared to
controls (Xu et al., 2012). These findings, combined with clinical
trials affirming the role of D-4F in improving HDL function and
reducing oxidative stress (Dunbar et al., 2017), support the use of
D-4F and other IRF5-targeting agents as a potential therapeutic
strategy to protect against SSc-induced cardiac inflammation. It
should also be noted that immune cells, such as monocytes, myeloid
cells and B cells, express IRF5 at much higher levels than the heart,
meaning that the D-4F-induced changes in myocardial IRF5
expression could also be related to changes in myocardial
immune cell content (Xu et al., 2012).
The tight skin-2 (Tsk2/+) mouse
The Tsk2/+ mouse strain has many features of human SSc, including
fibrosis, ECM abnormalities and ANAs (Gentiletti et al., 2005;
Long et al., 2014). Notably, Tsk2/+ mice have detectable levels of
anti-Topo-I autoantibodies (Gentiletti et al., 2005), which are
the most frequently observed autoantibodies in SSc patients that
have developed pulmonary fibrosis and cardiac complications
(Hesselstrand et al., 2003). As of now, there are no studies on
cardiac phenotypes in the Tsk2/+ mouse strain. However, presence
of anti-Topo-I autoantibodies may make them a suitable model for
future studies.
Engineered SSc models
A wide range of engineered SSc models exists. However, the
majority have been developed by specifically targeting pathways
involved in fibrosis or vascular function, and have no underlying
inflammatory or auto-immune component. We identified Fra-2
transgenic and UPAR−/−mice as two potentially relevant models of
autoimmunity. However, although the cardiac manifestations
documented in these mice appear comparable to the phenotype
observed in human patients, the underlying cause of cardiac disease
is clearly distinct.
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Fra-2
Compared to healthy controls, cardiac tissue from human SSc
patients has increased levels of Fra-2, a constituent of the
transcription factor AP-1 that controls a variety of stress responses
such as cell proliferation, apoptosis, inflammation and wound
healing (Venalis et al., 2015). In Fra-2 transgenic mice, the Fra-2
gene is ectopically expressed throughout the body. Fra-2 mice
develop microangiopathy (Box 1) and generalised fibrosis
predominantly in the skin and lungs. This is associated with
vascular remodelling, including intimal thickening, and obliteration
of the pulmonary arteries (Eferl et al., 2008). Unlike in human SSc,
these mice do not develop antibodies against endothelial cells or
Topo I. Moreover, fibrosis still arises if B and T cells are ablated,
which strongly argues against an autoimmune aetiology (Maurer
et al., 2013).
Fra-2mice have a decreased capillary density in the myocardium
and an increase in the number of apoptotic endothelial cells.
Perivascular inflammation, comprising mainly T cells, and
increased myocardial fibrosis are also present, accompanied by an
increase in myofibroblasts (Venalis et al., 2015).
Although the aetiology of disease in Fra-2mice is most likely not
autoimmune, this model may be useful to study the implications of
increased Fra-2 expression in SSc patient hearts.
Urokinase-type plasminogen activator receptor (uPAR)−/−
uPAR is widely expressed in haematopoietic and endothelial cells,
fibroblasts, and myofibroblasts. It has anti-apoptotic effects and is
involved in ECM remodelling and degradation, as well as cell
differentiation, proliferation, adhesion and migration (Ragno, 2006).
Loss of function of the uPA/uPAR system in endothelial cells is
involved in SSc-related microvascular abnormalities and impaired
angiogenesis (D’Alessio et al., 2004). Cleavage of uPAR is also a
crucial step in the differentiation of fibroblasts into myofibroblasts
(Bernstein et al., 2007), and uPAR gene deficiency is involved in the
pathogenesis and progression of fibrosis in the skin and kidneys
of mice (Zhang et al., 2002; Kanno et al., 2008). uPAR−/− mice
display the main histopathological features of human SSc, including
dermal and pulmonary fibrosis, peripheral microvasculopathy and
endothelial cell apoptosis. In addition, they have increased dermal
thickness, collagen content, myofibroblast numbers and expression of
profibrotic factors such as TGF-β (Manetti et al., 2014).
uPAR−/− mice also exhibit the typical histopathological features
of SSc cardiomyopathy, including interstitial and perivascular
fibrosis (Box 1) in the myocardium, foci of cardiomyocyte damage
with contraction band necrosis, endothelial cell apoptosis, reduced
capillary density, profibrotic myofibroblast differentiation and
patchy collagen accumulation in interstitial and perivascular areas
of the myocardium. However, it has been suggested that fibrosis
in these mice primarily arises as a consequence of fibroblast
reprogramming, which is supported by the lack of inflammation in
the myocardium (Wang et al., 2012). Despite a well-characterised
cardiac phenotype, the uPAR−/− model is therefore unlikely to be
suitable for immunological questions.
Non-rodent models of systemic autoimmunity
Rodents represent the overwhelming majority of animals used for
immunological research. However, a few non-rodent models of
systemic autoimmunity do exist. Recently, the susceptibility to
heterogeneous collagen II for arthritis induction was confirmed in
minipigs, providing the first large-animal model for RA, which
might prove very valuable for future studies on cardiac pathology
(Lee et al., 2016).
Interestingly, for SSc, the University of California at Davis line 200
(UCD-200) chicken is the only animal model displaying all the
hallmarks of human SSc, i.e. vascular occlusion, severe perivascular
lymphocytic infiltration of skin and viscera, fibrosis of skin and
internal organs, ANAs, and distal polyarthritis (Wick et al., 2006).
These chickens spontaneously develop an inherited scleroderma-like
diseasewith an initial inflammatory stage, progressing to fibrosis with
collagen accumulation in the affected tissues. Alterations start in the
skin within the first week after hatching and then extend to internal
organs including the heart. A total of 90% of the birds are afflicted at
the age of 5 weeks (Sgonc and Wick, 2009).
Animal welfare and husbandry considerations, and unique
opportunities for genetic manipulation and imaging techniques,
have also led to a surge of immunological studies in zebrafish
(Renshaw and Trede, 2012). Although the zebrafish innate immune
system is now well-characterised (Novoa and Figueras, 2012),
information on adaptive immunity is still scarce and models for
systemic autoimmunity are not yet established.
Summary and conclusions
Despite their significant clinical relevance, cardiac manifestations
have so far rarely been the focus of experimental studies into
autoimmune disease. The available literature is sparse and often
limited to the first description and basic phenotypic characterisation
of the respective mouse model. This means that, for most models,
despite being well-established for immunological research, the
mechanisms underlying cardiac involvement are not yet understood.
More basic research is needed to allow direct comparison between
cardiac disease mechanisms in human patients and the respective
model. However, due to significant progress in our understanding of
the immuno-cardio crosstalk, access to this information is becoming
important to allow researchers to choose suitable models. Besides
the phenotypic information provided above, we recommend that
researchers also consider the following general challenges that are
involved in attempting to model human disease using mice.
Complex pathophysiology of systemic autoimmune disease
Faithful modelling of diseases with aetiologies and phenotypic
manifestations as diverse as those observed in systemic
autoimmunity is immensely challenging. Pathological pathways
underlying organ damage in systemic autoimmunity are many-fold
and interconnected, and identification of a single triggering event
or molecular culprit has not been possible so far. SLE has in fact
been suggested to encompass several different disease groups
(Toro-Domínguez et al., 2018). This opens the possibility for
patient stratification and targeted investigation of aetiology and
mechanisms in specific patient groups. In the meantime, researchers
commonly resort to models that phenocopy selected manifestations
of disease, and the use of several different models in parallel is
highly recommended.
Environmental factors
A common concern with mouse models is that laboratory mice
are born and maintained in controlled conditions with little
correspondence to the human environment (Sundberg and
Schofield, 2018). This is particularly relevant for immunological
studies, which are known to show strong sensitivity to changes in diet,
the microbiota, or the absence or presence of environmental microbes
(Mu et al., 2017; Johnson et al., 2015). Careful experimental design
and confirmation experiments in separate animal facilities, which
differ in standard diet and repertoire of environmental microbes, may
help to avoid spurious results and limit this concern.
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Genetic diversity
Current studies inmousemodels rely heavily on inbredmouse strains;
however, these cannot mimic the genetically diverse human
population. Yet, variable susceptibility based on genetic variation
has emerged as a critical factor determining the risk of developing
autoimmunity as well as determining the main target organ in
systemic autoimmunity (Almlöf et al., 2017; Lanata et al., 2018).
Importantly, mouse genetic diversity panels have been generated to
overcome this limitation. For example, the Collaborative Cross
mouse diversity panel has been obtained from systematically
crossing eight inbred founder strains (A/J, C57BL/6J, 129S1/
SvImJ, NOD/ShiLtJ, NZO/H1LtJ, CAST/EiJ, PWK/PhJ and WSB/
EiJ) (Iraqi et al., 2012). They provide the opportunity to identify
genetic influences on manifestations of autoimmunity.
Inter-species differences in basic physiology
While cardiovascular system proteins, including myosin and
troponin, are highly conserved, the immune system is under high
evolutionary pressure from pathogens (Fumagalli et al., 2011).
Therefore, mouse and human immunological factors may differ,
which may affect direct translatability from model to patients.
However, while individual molecules may have changed throughout
evolution, the overall function of cells and networks often remains the
same (Monaco et al., 2015). Thus, a specific target identified in
mouse models needs to be carefully validated in humans, but it is
likely that the functional pathways involved are similar.
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Cardiovascular disease in inflammatory rheumatic diseases. Best Pract. Res.
Clin. Rheumatol. 30, 851-869.
Celhar, T. and Fairhurst, A. M. (2017). Modelling clinical systemic lupus
erythematosus: similarities, differences and success stories. Rheumatology
(Oxf.) 56, i88-i99.
Champion, H. C. (2008). The heart in scleroderma.Rheum. Dis. Clin. North Am. 34,
181-.
Christensen, S. R. and Shlomchik, M. J. (2007). Regulation of lupus-related
autoantibody production and clinical disease by Toll-like receptors. Semin.
Immunol. 19, 11-23.
Courtenay, J. S., Dallman, M. J., Dayan, A. D., Martin, A. and Mosedale, B.
(1980). Immunisation against heterologous type II collagen induces arthritis in
mice. Nature 283, 666-668.
Crow, M. K., Olferiev, M. and Kirou, K. A. (2015). Targeting of type i interferon in
systemic autoimmune diseases. Transl. Res. 165, 296-305.
D’Alessio, S., Fibbi, G., Cinelli, M., Guiducci, S., Del Rosso, A., Margheri, F.,
Serratì, S., Pucci, M., Kahaleh, B., Fan, P. et al. (2004). Matrix metalloproteinase
12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular
endothelial cells results in impaired angiogenesis. Arthritis. Rheum. 50,
3275-3285.
Denton, C. P. and Khanna, D. (2017). Systemic sclerosis. Lancet 390, 1685-1699.
Dong, C., Winters, G. L., Wilson, J. E. and McManus, B. M. (1997). Enhanced
lymphocyte longevity and absence of proliferation and lymphocyte apoptosis in
Quilty effects of human heart allografts. Am. J. Pathol. 151, 121-130.
Dunbar, R. L., Movva, R., Bloedon, L. T., Duffy, D., Norris, R. B., Navab, M.,
Fogelman, A. M. and Rader, D. J. (2017). Oral apolipoprotein A-I mimetic D-4F
lowers HDL-inflammatory index in high-risk patients: a first-in-human multiple-
dose, randomized controlled trial. Clin. Transl. Sci. 10, 455-469.
Eferl, R., Hasselblatt, P., Rath, M., Popper, H., Zenz, R., Komnenovic, V.,
Idarraga, M.-H., Kenner, L. and Wagner, E. F. (2008). Development of
pulmonary fibrosis through a pathway involving the transcription factor Fra-2/
AP-1. Proc. Natl. Acad. Sci. USA 105, 10525-10530.
Ehlers, M., Fukuyama, H., McGaha, T. L., Aderem, A. and Ravetch, J. V. (2006).
TLR9/MyD88 signaling is required for class switching to pathogenic IgG2a and 2b
autoantibodies in SLE. J. Exp. Med. 203, 553-561.
Eriksson, U. and Penninger, J. M. (2005). Autoimmune heart failure: new
understandings of pathogenesis. Int. J. Biochem. Cell Biol. 37, 27-32.
Ewald, S. E. and Barton, G. M. (2011). Nucleic acid sensing Toll-like receptors in
autoimmunity. Curr. Opin. Immunol. 23, 3-9.
Fallarino, F., Grohmann, U., Vacca, C., Bianchi, R., Fioretti, M. C. and Puccetti,
P. (2002). CD40 ligand and CTLA-4 are reciprocally regulated in the Th1 cell
proliferative response sustained by CD8(+) dendritic cells. J. Immunol. 169,
1182-1188.
Ferri, C., Valentini, G., Cozzi, F., Sebastiani, M., Michelassi, C., La Montagna,
G., Bullo, A., Cazzato, M., Tirri, E., Storino, F. et al. (2002). Systemic sclerosis:
demographic, clinical, and serologic features and survival in 1,012 Italian patients.
Medicine (Baltim.). 81, 139-153.
Ferri, C., Giuggioli, D., Sebastiani, M., Colaci, M. and Emdin, M. (2005). Heart
involvement and systemic sclerosis. Lupus 14, 702-707.
Fisman, E. Z., Benderly, M., Esper, R. J., Behar, S., Boyko, V., Adler, Y., Tanne,
D., Matas, Z. and Tenenbaum, A. (2006). Interleukin-6 and the risk of future
cardiovascular events in patients with angina pectoris and/or healed myocardial
infarction. Am. J. Cardiol. 98, 14-18.
Fossati, L., Sobel, E. S., Iwamoto, M., Cohen, P. L., Eisenberg, R. A. and Izui, S.
(1995). The Yaa gene-mediated acceleration of murine lupus: Yaa−T cells from
non-autoimmune mice collaborate with Yaa+B cells to produce lupus
autoantibodies in vivo. Eur. J. Immunol. 25, 3412-3417.
Fraser, W. J., Haffejee, Z. and Cooper, K. (1995). Rheumatic Aschoff nodules
revisited: an immunohistological reappraisal of the cellular component.
Histopathology 27, 457-461.
13
REVIEW Disease Models & Mechanisms (2019) 12, dmm036947. doi:10.1242/dmm.036947
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
Fumagalli, M., Sironi, M., Pozzoli, U., Ferrer-Admettla, A., Pattini, L. and
Nielsen, R. (2011). Signatures of environmental genetic adaptation pinpoint
pathogens as the main selective pressure through human evolution. PLoS Genet.
Gentiletti, J., McCloskey, L. J., Artlett, C. M., Peters, J., Jimenez, S. A. and
Christner, P. J. (2005). Demonstration of autoimmunity in the tight skin-2 mouse:
a model for scleroderma. J. Immunol. 175, 2418-2426.
Ghosh, S., Hoenerhoff, M. J., Clayton, N., Myers, P., Stumpo, D. J., Maronpot,
R. R. and Blackshear, P. J. (2010). Left-sided cardiac valvulitis in tristetraprolin-
deficient mice: the role of tumor necrosis factor α. Am. J. Pathol. 176, 1484-1493.
Giles, J. T., Fert-Bober, J., Park, J. K., Bingham, C. O., Andrade, F., Fox-Talbot,
K., Pappas, D., Rosen, A., van Eyk, J., Bathon, J. M. et al. (2012). Myocardial
citrullination in rheumatoid arthritis: a correlative histopathologic study. Arthritis
Res. Ther. 14, R39.
Gomez-Guzman, M., Jimenez, R., Romero, M., Sanchez, M., Zarzuelo, M. J.,
Gomez-Morales, M., O’Valle, F., Lopez-Farre, A. J., Algieri, F., Galvez, J. et al.
(2014). Chronic hydroxychloroquine improves endothelial dysfunction and
protects kidney in a mouse model of systemic lupus erythematosus.
Hypertension 64, 330-337.
Green, M. C., Sweet, H. O. and Bunker, L. E. (1976). Tight-skin, a new mutation of
the mouse causing excessive growth of connective tissue and skeleton.
Am. J. Pathol. 82, 493-512.
Guerard, S., Boieri, M., Hultqvist, M., Holmdahl, R. and Wing, K. (2016a). The
SKG mutation in ZAP-70 also confers arthritis susceptibility in C57 black mouse
strains. Scand. J. Immunol. 84, 3-11.
Guerard, S., Holmdahl, R. and Wing, K. (2016b). Reactive oxygen species
regulate innate but not adaptive inflammation in ZAP70-mutated SKG arthritic
mice. Am. J. Pathol. 186, 2353-2363.
Hagiwara, Y., Miyoshi, S., Fukuda, K., Nishiyama, N., Ikegami, Y., Tanimoto, K.,
Murata, M., Takahashi, E., Shimoda, K., Hirano, T. et al. (2007). SHP2-
mediated signaling cascade through gp130 is essential for LIF-dependent ICaL,
[Ca2+]itransient, and APD increase in cardiomyocytes. J. Mol. Cell. Cardiol. 43,
710-716.
Han, C., Robinson, D. W., Hackett, M. V., Paramore, L. C., Fraeman, K. H. and
Bala, M. V. (2006). Cardiovascular disease and risk factors in patients with
rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J. Rheumatol.
33, 2167-2172.
Han, S., Zhuang, H., Shumyak, S., Yang, L. and Reeves, W. H. (2015).
Mechanisms of autoantibody production in systemic lupus erythematosus. Front.
Immunol. 6, 228.
Hang, L. M., Izui, S. and Dixon, F. J. (1981). (NZW x BXSB)F1 hybrid. A model of
acute lupus and coronary vascular disease with myocardial infarction. J. Exp.
Med. 154, 216-221.
Hasham, M. G., Baxan, N., Stuckey, D. J., Branca, J., Perkins, B., Dent, O.,
Duffy, T., Hameed, T. S., Stella, S. E., Bellahcene, M. et al. (2017). Systemic
autoimmunity induced by the TLR7/8 agonist Resiquimod causesmyocarditis and
dilated cardiomyopathy in a newmouse model of autoimmune heart disease. Dis.
Model. Mech. 10, 259-270.
He, M., Liang, X., He, L., Wen, W., Zhao, S., Wen, L., Liu, Y., Shyy, J. Y.-J. and
Yuan, Z. (2013). Endothelial dysfunction in rheumatoid arthritis: the role of
monocyte chemotactic protein-1-induced protein. Arterioscler. Thromb. Vasc.
Biol. 33, 1384–1391.
Hemnes, A. R., Zaiman, A. and Champion, H. C. (2008). PDE5A inhibition
attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension
through inhibition of ROS generation and RhoA/Rho kinase activation.
Am. J. Physiol. - Lung Cell. Mol. Physiol. 294, L24-L33.
Hesselstrand, R., Scheja, A., Shen, G. Q., Wiik, A. and Åkesson, A. (2003). The
association of antinuclear antibodies with organ involvement and survival in
systemic sclerosis. Rheumatology 42, 534-540.
Ho, K. T. and Reveille, J. D. (2003). The clinical relevance of autoantibodies in
scleroderma. Arthritis Res. Ther. 5, 80-93.
Hobday, P. M., Auger, J. L., Schuneman, G. R., Haasken, S., Verbeek, J. S. and
Binstadt, B. A. (2014). Fcγ receptor III and Fcγ receptor IV on macrophages drive
autoimmune valvular carditis in mice. Arthritis Rheumatol. 66, 852-862.
Hsieh, C., Imhof, I., Li, L., Niemi, E., Bell, M., Karliner, J. and Nakamura, M.
(2017). Cardiac immune cells in SKG mice with inflammatory arthritis before and
after myocardial infarction. Am. J. Rheumatol. 69 (suppl. 10).
Iraqi, F. A., Mahajne, M., Salaymah, Y., Sandovski, H., Tayem, H., Vered, K.,
Balmer, L., Hall, M., Manship, G., Morahan, G. et al. (2012). The genome
architecture of the collaborative cross mouse genetic reference population.
Genetics 190, 389-401.
Ishikawa, H., Takeda, K., Okamoto, A., Matsuo, S. and Isobe, K. (2009). Induction
of autoimmunity in a bleomycin-induced murine model of experimental systemic
sclerosis: an important role for CD4+ T cells. J. Invest. Dermatol. 129, 1688-1695.
Iveson, J. M. I., Thadani, U., Ionescu, M. and Wright, V. (1975). Aortic valve
incompetence and replacement in rheumatoid arthritis. Ann. Rheum. Dis. 34,
312-320.
Jaffee, B. D. and Claman, H. N. (1983). Chronic graft-versus-host disease (GVHD)
as a model for scleroderma. I. Description of model systems. Cell. Immunol. 77,
1-12.
Jain, D. and Halushka, M. K. (2009). Cardiac pathology of systemic lupus
erythematosus. J. Clin. Pathol. 62, 584-592.
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J. P. (2015). A comparison of human and mouse gene co-expression networks
reveals conservation and divergence at the tissue, pathway and disease levels.
BMC Evol. Biol. 15, 259.
Monneaux, F., Dumortier, H., Steiner, G., Briand, J.-P. and Muller, S. (2001).
Murine models of systemic lupus erythematosus: B and T cell responses to
spliceosomal ribonucleoproteins in MRL/Fas(lpr) and (NZB x NZW)F(1) lupus
mice. Int. Immunol. 13, 1155-1163.
Moyssakis, I., Tektonidou, M. G., Vasilliou, V. A., Samarkos, M., Votteas, V. and
Moutsopoulos, H. M. (2007). Libman-sacks endocarditis in systemic lupus
erythematosus: prevalence, associations, and evolution. Am. J. Med. 120,
636-642.
Mu, Q., Zhang, H., Liao, X., Lin, K., Liu, H., Edwards, M. R., Ahmed, S. A., Yuan,
R., Li, L., Cecere, T. E. et al. (2017). Control of lupus nephritis by changes of gut
microbiota. Microbiome 5, 73.
Murphy, E. D. and Roths, J. B. (1978). A single gene model for massive
lymphoproliferation with immune complex disease in new mouse strain MRL.
Faculty Research 1970-1979, 955. In Topics In Hematology, Proc 16th Internat
Cong Hematol, 1976 (ExcMed Internat Cong Ser No 415), pp. 69-72. Amsterdam:
Excerpta Medica.
Murphy, A. M., Wong, A. L. and Bezuhly, M. (2015). Modulation of angiotensin II
signaling in the prevention of fibrosis. Fibrogenes. Tissue Repair 8, 7.
Naranjo, A., Sokka, T., Descalzo, M. A., Calvo-Alén, J., Hørslev-Petersen, K.,
Luukkainen, R. K., Combe, B., Burmester, G. R., Devlin, J., Ferraccioli, G.
et al. (2008). Cardiovascular disease in patients with rheumatoid arthritis: results
from the QUEST-RA study. Arthritis Res. Ther. 10, R30.
Nishimura, H. and Honjo, T. (2001). PD-1: An inhibitory immunoreceptor involved
in peripheral tolerance. Trends Immunol. 22, 265-268.
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A.,
Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N. et al. (2001). Autoimmune
dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291, 319-322.
Novoa, B. and Figueras, A. (2012). Zebrafish: Model for the study of inflammation
and the innate immune response to infectious diseases. Adv. Exp. Med. Biol. 946,
253-275.
Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida,
M., Hiai, H., Matsumori, A., Minato, N. et al. (2003). Autoantibodies against
cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient
mice. Nat. Med. 9, 1477-1483.
Olferiev, M., Kirou, K. A., Lundsgaard, D., Frederiksen, K. S. and Fleckner, J.
(2011). Analysis of longitudinal gene and protein expression data classifies SLE
patients based on molecular profiles associated with disease activity, serology
and specific organ manifestations. Arthritis. Rheum.
Omdal, R., Lunde, P., Rasmussen, K., Mellgren, S. I. and Husby, G. (2001).
Transesophageal and transthoracic echocardiography and Doppler-examinations
in systemic lupus erythematosus. Scand. J. Rheumatol. 30, 275-281.
Osborn, T. G., Bashey, R. I., Moore, T. L. and Fischer, V. W. (1987). Collagenous
abnormalities in the heart of the tight-skin mouse. J. Mol. Cell. Cardiol. 19,
581-587.
Pablos, J. L., Everett, E. T. and Norris, J. S. (2004). The tight skin mouse: an
animal model of systemic sclerosis.Clin. Exp. Rheumatol. 22 Suppl. 33, S81-S85.
Palma Zochio Tozzato, G., Taipeiro, E. F., Spadella, M. A., Marabini Filho, P., de
Assis, M. R., Carlos, C. P., Girol, A. P. and Chies, A. B. (2016). Collagen-
induced arthritis increases inducible nitric oxide synthase not only in aorta but also
in the cardiac and renal microcirculation of mice. Clin. Exp. Immunol. 183,
341-349.
Pansky, B. and Freimer, E. H. (1974). Spontaneous carditis in the NZB mouse and
its hybrids. Arthritis. Rheum. 17, 403-408.
Parameswaran, N. and Patial, S. (2010). Tumor necrosis factor-alpha signaling in
macrophages. Crit. Rev. Eukaryot. Gene Expr. 20, 87-103.
Perry, D., Sang, A., Yin, Y., Zheng, Y.-Y. and Morel, L. (2011). Murine models of
systemic lupus erythematosus. J. Biomed. Biotechnol. 2011, 271694.
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